Constellation Pharmaceuticals (CNST) Announces Earnings Results

Share on StockTwits

Constellation Pharmaceuticals (NASDAQ:CNST) announced its quarterly earnings data on Thursday. The company reported ($0.81) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.67) by ($0.14), Fidelity Earnings reports.

Shares of NASDAQ:CNST traded down $0.23 during midday trading on Friday, hitting $5.86. The company had a trading volume of 6,229 shares, compared to its average volume of 19,381. Constellation Pharmaceuticals has a 12 month low of $5.57 and a 12 month high of $12.21.

A number of research analysts have commented on CNST shares. Cann started coverage on Constellation Pharmaceuticals in a research report on Monday, August 13th. They issued an “outperform” rating and a $21.00 price objective on the stock. BMO Capital Markets started coverage on Constellation Pharmaceuticals in a research report on Monday, August 13th. They issued an “outperform” rating and a $19.00 price objective on the stock. JPMorgan Chase & Co. started coverage on Constellation Pharmaceuticals in a research report on Monday, August 13th. They issued an “overweight” rating and a $17.00 price objective on the stock. Oppenheimer started coverage on Constellation Pharmaceuticals in a research report on Monday, August 13th. They issued an “outperform” rating and a $21.00 price objective on the stock. Finally, Zacks Investment Research upgraded Constellation Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price objective on the stock in a research report on Monday, October 15th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company. Constellation Pharmaceuticals currently has an average rating of “Buy” and an average target price of $17.15.

COPYRIGHT VIOLATION NOTICE: This story was originally published by Week Herald and is owned by of Week Herald. If you are reading this story on another domain, it was illegally copied and reposted in violation of US & international copyright law. The legal version of this story can be read at https://weekherald.com/2018/11/10/constellation-pharmaceuticals-cnst-announces-earnings-results.html.

About Constellation Pharmaceuticals

Constellation Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression or drug resistance. The company's lead product candidate CPI-1205 that is in Phase Ib/II clinical trials for the treatment of metastatic castration-resistant prostate cancer in combination with androgen receptor signaling inhibitors, as well as for the treatment of solid tumors in combination with immune checkpoint inhibitors.

Further Reading: Trading Strategy Methods for Individual Investors

Receive News & Ratings for Constellation Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Constellation Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply